REGENXBIO

Gene Therapy Biotechnology Company

9804 Medical Center Dr. Fourth Floor Rockville MD 20850, Rockville, MD  ·  PATRICK CHRISTMAS

Filings
24
Clients
1
Total Income
Years Active
2018–2023

Filings

Year Client Period Income Expenses Doc
2023 REGENXBIO 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Termination
$91,000
2023 REGENXBIO 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$94,000
2023 REGENXBIO 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$90,000
2023 REGENXBIO 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$163,000
2022 REGENXBIO 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$70,000
2022 REGENXBIO 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$70,000
2022 REGENXBIO 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$82,000
2022 REGENXBIO 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$150,000
2021 REGENXBIO 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$60,000
2021 REGENXBIO 3rd Quarter (July 1 - Sep 30)
AMENDED
$75,000
Page 1 of 3  ·  24 filings Next

Clients Represented

ClientFilingsTotal Income
REGENXBIO 24

Lobbyists

NameDisclosed Prior Position
BRUCE ARTIM Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Su…